These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 3733242)

  • 21. Aluminum-related osteomalacia in renal-failure patients.
    Vick KE; Johnson CA
    Clin Pharm; 1985; 4(4):434-9. PubMed ID: 3899471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Detecting and evaluating hyperaluminemia in 3 dialysis centers].
    Balabán D; Simícková J; Kubátko J; Syrovátka P
    Cas Lek Cesk; 1989 Dec; 128(51):1611-4. PubMed ID: 2631999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Aluminum and uremic bone disease. Diagnostic utility of serum aluminum and the deferoxamine (DFO) test ].
    Jarava C; Armas JR; Palma A
    Nefrologia; 2001; 21(2):174-81. PubMed ID: 11464651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thrombocytopenia associated with intravenous desferrioxamine.
    Walker JA; Sherman RA; Eisinger RP
    Am J Kidney Dis; 1985 Oct; 6(4):254-6. PubMed ID: 4050784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aluminum intoxication of bone in renal failure--fact or fiction?
    Malluche HH; Faugere MC; Smith AJ; Friedler RM
    Kidney Int Suppl; 1986 Feb; 18():S70-3. PubMed ID: 3458000
    [No Abstract]   [Full Text] [Related]  

  • 26. [The K/DOQI guidelines on diagnosis and treatment of aluminum bone disease in hemodialysis patients].
    Nakazawa R
    Clin Calcium; 2004 May; 14(5):738-43. PubMed ID: 15577035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of aluminum-induced osteopathy with desferrioxamine in dialysis-dependent renal failure].
    Lechleitner P; Gmeiner R; Beck G; König P
    Wien Med Wochenschr; 1987 Aug; 137(14-15):355-60. PubMed ID: 3673100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Indirect methods for the diagnosis of aluminum bone disease: plasma aluminum, the desferrioxamine infusion test, and serum iPTH.
    Nebeker HG; Andress DL; Milliner DS; Ott SM; Alfrey AC; Slatopolsky EA; Sherrard DJ; Coburn JW
    Kidney Int Suppl; 1986 Feb; 18():S96-9. PubMed ID: 3458006
    [No Abstract]   [Full Text] [Related]  

  • 29. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
    McCarthy JT; Milliner DS; Johnson WJ
    Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rapid conversion from aluminium bone disease to hyperparathyroid bone disease by desferrioxamine.
    Terao N; Suzuki M; Homma S; Asano Y; Hosoda S; Furuse M
    Nihon Jinzo Gakkai Shi; 1988 Sep; 30(9):1129-33. PubMed ID: 3216555
    [No Abstract]   [Full Text] [Related]  

  • 31. Case report 294. Diagnosis: dialysis osteomalacia with response to desferrioxamine therapy.
    Xipell JM; Ham KN; Brown DJ; Dawborn JK
    Skeletal Radiol; 1984; 12(4):298-302. PubMed ID: 6505735
    [No Abstract]   [Full Text] [Related]  

  • 32. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
    Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Osteomalacia as a result of aluminum poisoning during chronic hemodialysis].
    Cournot-Witmer G; Gagnadoux MF; Lebon P; Broyer M; Balsan S
    Arch Fr Pediatr; 1982 Dec; 39 Suppl 2():749-54. PubMed ID: 6762177
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of an erythrocyte aluminum assay in the diagnosis of aluminum-associated microcytic anemia in patients undergoing dialysis and response to deferoxamine therapy.
    Abreo K; Brown ST; Sella M; Trapp G
    J Lab Clin Med; 1989 Jan; 113(1):50-7. PubMed ID: 2909650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Newcastle bone disease in Hong Kong: a study of aluminum associated osteomalacia.
    Chan MK; Varghese Z; Li MK; Wong WS; Li CS
    Int J Artif Organs; 1990 Mar; 13(3):162-8. PubMed ID: 2189835
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The causes, diagnosis and treatment of aluminum toxicity in patients with chronic renal failure undergoing dialysis].
    Wang G; Zhu P; Wang S
    Zhonghua Nei Ke Za Zhi; 1996 Jan; 35(1):36-40. PubMed ID: 9275645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aluminum and renal osteodystrophy.
    Nebeker HG; Coburn JW
    Annu Rev Med; 1986; 37():79-95. PubMed ID: 3085581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effects of discontinuation of aluminum exposure on aluminum-induced osteomalacia.
    Finch JL; Bergfeld M; Martin KJ; Chan YL; Teitelbaum S; Slatopolsky E
    Kidney Int; 1986 Sep; 30(3):318-24. PubMed ID: 3784278
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of low aluminum water and desferrioxamine on the outcome of dialysis encephalopathy.
    Milne FJ; Sharf B; Bell P; Meyers AM
    Clin Nephrol; 1983 Oct; 20(4):202-7. PubMed ID: 6641027
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and biochemical features of aluminum-related bone disease.
    Ihle BU; Becker GJ; Kincaid-Smith PS
    Kidney Int Suppl; 1986 Feb; 18():S80-6. PubMed ID: 3458003
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.